Catalent, Inc. today announced it has commenced a $200 million capital investment in its Biologics business to expand drug substance manufacturing capacity and drug product fill/finish capacity due to projected growth among existing and future customers.

Catalent today announced that following the site’s twentieth commercial product approval, it is investing nearly $14 million to expand biologics packaging capabilities and capacity at its Bloomington, Indiana, biologics manufacturing facility.

Catalent today announced that two of its experts have been invited to speak at the upcoming Waterside Conference.

Catalent today announced that one of its scientific experts will host a workshop during KNect365 Life Sciences’ annual Well Characterized Biologics & Biological Assays conference (WCBBA).

Catalent today announced that Christopher Hepler, Group Leader, Biologics Analytical Services, Catalent Biologics has been invited to speak at the upcoming 16th Annual Congress of International Drug Discovery Science & Technology.

Catalent Pharma Solutions and Berkeley Lights, Inc., a leader in digital cell biology, today announced Catalent Biologics will adopt BLI’s Beacon® optofluidic platform to accelerate its cell line development workflow.

Catalent Pharma Solutions today announced that Graham Brearley, Ph.D., has been appointed as General Manager of the company’s Madison, Wisconsin facility.

Catalent today welcomed the news that InterveXion has enrolled the first patient in STAMPOUT, the first trial in methamphetamine users of the first-in-class anti-methamphetamine antibody IXT-m200.

Catalent and Valerius Biopharma AG, a Swiss biopharmaceutical company, today announced that they are to collaborate on the development and manufacture of Valerius’ biosimilar products.